latest News

OxStem Appoints Dr. Ian Churcher as Chief Scientific Officer and Announces Further C-suite Changes

OxStem Limited (“OxStem” or “The Company”) is pleased to announce the appointment of Dr. Ian Churcher to the role of Chief Scientific Officer (CSO). Ian Churcher has 22 years’ experience in pharmaceutical R&D obtained in positions of increasing seniority in international companies including Merck Sharp & Dohme (Merck), GlaxoSmithKline (GSK) and BenevolentAI. At BenevolentAI, Ian was SVP Drug Discovery with responsibility for leadership of a portfolio of drug discovery projects across several therapeutic areas, from target identification through lead optimisation to preclinical entry, working closely with machine learning experts to develop a cutting-edge AI drug discovery platform.

Please see our full press release here

OxStem Appoints Chief Executive Officer

OxStem Limited is pleased to announce the appointment of Dr Stuart Collinson to the role of Chief Executive Officer and Chairman.

Press release here.

Oxford Stem Cell Institute Symposium 2018 -  "Stem Cells: From Mechanism to Therapy” 


The 2018 Annual Oxford Stem Cell Institute Symposium "Stem Cells: From Mechanism to Therapy” will be held on the 12th and 13th November. at St Hugh’s College, St Margaret’s Road, Oxford. With researchers from Oxford, Cambridge, Europe and the US, the symposium will profile current research and challenges in our understanding of how stem cells can be manipulated for the development of effective regenerative medicine in a range of diseases including retinopathies, metabolic and genetic skin disorders, neurodegeneration, musculoskeletal disease, heart failure and cancer.  To register please visit: Numbers are restricted to 200 and so register early to ensure your place.

Prof Paul Riley Publishes Lymphangiogenesis Paper in Journal of Clinical Investigation

Prof Paul Riley, co-founder of OxStem Cardio, this month published work in the Journal of Clinical Investigation entitled "The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction". Prof Riley's findings support targeting of the lymphatic/immune cell axis as a therapeutic paradigm to promote immune modulation and heart repair.

More News